Sign Up
OverviewAPI
The ophthalmic drugs contract manufacturing market is driven by the rising prevalence of ophthalmic disorders, outsourcing manufacturing to contract development and manufacturing organizations (CDMOs) for cost efficiency, and technological innovations. The market is projected to grow at a CAGR of 6.4% during the forecast period 2023-2033, with major players including Lonza, Recipharm, Catalent Inc., Eurofins Scientific, and Thermo Fisher Scientific Inc.

Ask a question